



RECEIVED

APR 30 2003

TECH CENTER 1600/2000

~~Subst EU~~  
74. (Amended) The method of claim 67, wherein the pharmaceutical composition further comprises a second agent, wherein the second agent is selected from the group consisting of an anti-histamine, a mast cell stabilizer, a non-antibiotic anti-microbial agent, an anti-leukotriene, an anti-viral, an antiseptic, a non-steroidal anti-inflammatory, a combination of at least two antibiotics, an agent for treating nasal polyps, an anticholinergic agent and combinations thereof.

~~Subst EU~~  
86. (Amended) The method of claim 74, wherein the second agent is a non-antibiotic anti-microbial agent.

~~Subst EU~~  
93. (New) The method of claim 67, wherein the composition has an osmolality of about 300 mOsm/kg to about 880 mOsm/kg.

~~Subst EU~~  
94. (New) The method of claim 67, wherein the composition has an osmolality of about 400 mOsm/kg to about 700 mOsm/kg.

95. (New) The method of claim 67, wherein the composition has an osmolality of about 500 mOsm/kg to about 600 mOsm/kg.

96. (New) The method of claim 67, wherein the surfactant has a hydrophile-lipophile-balance (HLB) of between about 1.8 to about 8.6.

97. (New) The method of claim 67, wherein the surfactant has a hydrophile-lipophile-balance (HLB) of between about 9.6 to about 16.7.

98. (New) The method of claim 67, wherein the composition has a pH of about 3.0 to about 8.5.

U.S.S.N 09/942,959  
Osbakken *et al.*  
PRELIMINARY AMENDMENT

~~99.~~ (New) The method of claim 67, wherein the composition comprises particles in the size range of about 1.0 to about 4.0  $\mu\text{m}$  in diameter.

100. (New) The method of claim 67, wherein the composition comprises particles in the size range of about 0.5 to about 5.0  $\mu\text{m}$  in diameter.

101. (New) The method of claim 67, wherein the composition comprises particles in the size range of about 2.0 to about 3.5  $\mu\text{m}$  in diameter.

*Sub E*  
~~102.~~ (New) The method of claim 67, wherein the composition comprises less than about 20% total particles having a diameter of about 5  $\mu\text{m}$ .

*DH*  
103. (New) The method of claim 67, wherein the composition has an NaCl equivalency of about 1.1% NaCl to about 1.8% NaCl.

104. (New) The method of claim 67, wherein the composition has an NaCl equivalency of about 1.3% NaCl to about 1.7% NaCl.

105. (New) The method of claim 67, wherein the pharmaceutical composition is administered to the patient 1-3 times a day for a total of 14-21 days.

106. (New) The method of claim 68, wherein the nebulizer delivers a majority of aerosolized particles in the size range of about 3.0 to about 3.5  $\mu\text{m}$  in diameter.

107. (New) The method of claim 68, wherein the nebulizer delivers a majority of aerosolized particles in the size range of about 1.0 to about 4.0  $\mu\text{m}$  in diameter.

**U.S.S.N 09/942,959**  
**Osbakken *et al.***  
**PRELIMINARY AMENDMENT**

~~108. (New) The method of claim 68, wherein the nebulizer delivers a majority of aerosolized particles in the size range of about 0.5 to about 5.0  $\mu\text{m}$  in diameter.~~

~~109. (New) The method of claim 68, wherein the nebulizer delivers a majority of aerosolized particles in the size range of about 2.0 to about 3.5  $\mu\text{m}$  in diameter.~~

~~110. (New) The method of claim 68, wherein the maximum number of particles delivered by the nebulizer over about 5.0 microns is less than 20% of the total particles.~~

*DX*  
*Subj*  
*E*

~~111. (New) A method of treating sinusitis, comprising the steps of: nasally administering a composition of any of claims 1-41 to a mammal diagnosed or suspected of having sinusitis, wherein the composition comprises an agent for treating sinusitis.~~

~~112. (New) The method of claim 74, wherein the second agent is a combination of at least two antibiotics.~~

~~113. (New) The method of claim 112, wherein the at least two antibiotics are selected from the group consisting of penicillins, cephalosporins, macrolides, ketolides, sulfonamides, quinolones, aminoglycosides, beta lactam antibiotics, and linezolid.~~

---

**REMARKS**

Any fees that may be due in connection with this application throughout its pendency may be charged to Deposit Account No. 50-1213.

Claims 68, 74, and 86 have been amended to correct obvious clerical